Cantor Fitzgerald Reiterates Overweight Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports.

A number of other analysts also recently commented on EOLS. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, August 1st.

Evolus Price Performance

NASDAQ:EOLS opened at $15.18 on Monday. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. Evolus has a one year low of $7.44 and a one year high of $16.29. The company has a fifty day moving average price of $13.44 and a 200 day moving average price of $13.00. The stock has a market cap of $957.71 million, a P/E ratio of -14.46 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. Analysts anticipate that Evolus will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Several large investors have recently added to or reduced their stakes in EOLS. Quest Partners LLC acquired a new position in shares of Evolus in the 2nd quarter worth approximately $43,000. Quarry LP acquired a new position in Evolus in the second quarter worth $54,000. Tradition Wealth Management LLC grew its holdings in shares of Evolus by 44.8% during the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after purchasing an additional 2,475 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in shares of Evolus during the fourth quarter worth $119,000. Finally, Profund Advisors LLC acquired a new stake in shares of Evolus in the second quarter valued at $130,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.